Cardiff Oncology (CRDF) has completed enrollment for the phase 2 trial assessing a combination of its onvansertib drug candidate with the standard of care in patients with first-line, RAS-mutated metastatic colorectal cancer.
Patients across 41 clinical sites in the US are randomized into either 20- or 30-milligram onvansertib plus standard of care, or standard of care alone. The study has a primary endpoint of an objective response rate and secondary endpoints including progression-free survival, duration of response and safety, the company said.
Cardiff said it expects to report additional clinical data from the mid-stage trial later during the current quarter.
Cardiff shares recently were fractionally higher during Tuesday's after-hours session.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。